This site is intended for Healthcare Professionals.
Reporting suspected adverse
EUA Fact Sheets for Vaccination Providers
EUA Fact Sheets for Recipients
UK, English
Menu
Close
Pfizer-BioNTech COVID-19 Vaccine Authorised for Emergency Use:
Emergency uses of the vaccine have not been approved or licensed by FDA, but have been authorised by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals 5 years of age and older. The emergency uses are only authorised for the duration of the declaration that circumstances exist justifying the authorisation of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorisation revoked sooner.
Formulation |
12 years of age and older |
12 years of age and older |
5 through 11 years of age |
---|---|---|---|
Vial |
Multi-dose Vial |
Multi-dose Vial |
Multi-dose Vial |
Vial Cap Color |
Purple |
Gray |
Orange |
EUA Fact Sheet for Vaccination Providers |
EUA Fact Sheet for Vaccination Providers |
EUA Fact Sheet for Vaccination Providers |
EUA Fact Sheet for Vaccination Providers |
Dosage |
30 mcg |
30 mcg |
10 mcg |
Injection Volume per Dose |
0.3 mL |
0.3 mL |
0.2 mL |
Dilution |
Dilution required |
NO DILUTION |
Dilution required |
Amount of Diluent |
1.8 mL |
NO DILUTION |
1.3 mL |
Doses per Vial |
6 doses per vial |
6 doses per vial |
10 doses per vial |
Vial Size |
2 mL |
2 mL |
2 mL |
Fill Volume per Vial |
0.45 mL |
2.25 mL |
1.3 mL |
Storage Conditions |
|||
Ultra-Low-Temperature (ULT) Freezer (-90°C to -60°C) |
9 months (shelf life)† |
9 months (shelf life)‡ |
9 months (shelf life)‡ |
Freezer Storage Time |
2 weeks |
DO NOT STORE |
DO NOT STORE |
Refrigeration Storage Time |
1 month |
10 weeks |
10 weeks |
Room Temperature |
2 hours prior to dilution |
12 hours prior to first puncture |
12 hours prior to dilution |
After First Puncture |
Discard after 6 hours |
Discard after 12 hours |
Discard after 12 hours |
Package Size |
195 vials |
10 vials |
10 vials |
*Diluent: sterile 0.9% Sodium Chloride Injection, USP. Bacteriostatic saline or other diluents must NOT be used.
†Regardless of storage condition, vaccine should not be used past the 9 month expiry (6 months printed on the vial plus additional 3 months for the expiry dates until February 2022. All vials with an expiry date beyond February 2022 will already reflect the 9-month shelf life).
‡Regardless of storage condition, vaccines should not be used after 9 months from the date of manufacture printed on the vial and cartons.
The Pfizer-BioNTech COVID-19 Vaccine has received Emergency Use Authorization (EUA) from FDA to prevent COVID-19 in individuals 5 years of age and older to provide:
a 10 mcg modRNA 2-dose primary series to individuals 5 through 11 years of age
a 30 mcg modRNA 2-dose primary series to individuals 12 years of age and older
a 10 mcg modRNA third primary series dose to individuals 5 through 11 years of age who have been determined to have certain kinds of immunocompromise
a 30 mcg modRNA third primary series dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise
a 30 mcg modRNA single booster dose to individuals 12 years of age and older who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine
a 30 mcg modRNA single booster dose to individuals 18 years of age and older who have completed primary vaccination with another authorised or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorised for a booster dose of the vaccine used for primary vaccination
Pfizer is committed to patient safety and ensuring that people have accurate information about the vaccine, including how it is accessed and administered. We are actively monitoring for fraudulent offers of illegitimate vaccines to protect patients from products that might be dangerous and lead to serious and life-threatening harm
The vaccine is only administered intramuscularly by a healthcare professional
The vaccine is not taken orally and is not available in a capsule or tablet form
Authentic vaccines, manufactured by Pfizer Inc., will include the Pfizer and BioNTech names on the label and are dispensed in a vial as follows:
For 12 years of age and older Dilute Before Use, Purple Cap, two versions of the vial label are in current circulation - with or without a purple border
For 12 years of age and older Do Not Dilute, Gray Cap, the vial label includes a gray border
For 5 through 11 years of age Dilute Before Use, Orange Cap, the vial label includes an orange border
Ensure the safety of the vaccine vials by limiting access to only authorised personnel. The location they are stored in must be secure and locked when not in use. To prevent counterfeits, discard vaccine vials in sharps containers and empty vial cartons as medical waste or deface or safely crush all materials so they cannot be reused. Remember, the vaccines are only available through government-authorised vaccination centers – such as doctor’s offices, authorised pharmacies, outpatient clinics, community vaccination locations, and hospitals. The vaccine can only be administered by licensed healthcare professionals, or other individuals that are approved vaccinators, at government-authorised vaccination sites. Individual doses are not for sale
If you suspect the vaccine you have purchased may be counterfeit, contact us at [INSERT LOCAL COUNTRY INFORMATION] .
If you suspect COMIRNATY COVID-19 mRNA Vaccine (nucleoside modified) you have purchased may be counterfeit, contact Customer Service at 0860 Pfizer (734937)
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via https://www.pfizersafetyreporting.com/#/en or [email protected] or call +27 0860 PFIZER (734 937)] and include batch/Lot number if available
Submit medical Inquiry with link to the following MI contact details: https://www.pfizermedicalinformation.co.za/en-za/covid-19-mrna-vaccine-bnt162
EUA Fact Sheet Updates
Please be aware that Pfizer-BioNTech COVID-19 Vaccine is now available in three formulations. For additional information on differences across age groups and formulations please see Vaccine Formulations Guide on the home page of this website.
Label Update: Effective 03 Jan 2022
2.3 Vaccination Schedule
A single Pfizer‑BioNTech COVID-19 Vaccine booster dose (0.3 mL) may be administered at least 5 months after completing a primary series of the Pfizer-BioNTech COVID-19 Vaccine to individuals 12 years of age and older.
A third primary series dose of the Pfizer-BioNTech COVID-19 Vaccine supplied in multiple dose vials with orange caps and labels with orange borders (0.2 mL) at least 28 days following the second dose is authorized for administration to individuals 5 through 11 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
Click below to view:
• EUA Fact Sheet for Vaccination Providers - 12 year of age and older Dilute Before Use, Purple Cap
• EUA Fact Sheet for Vaccination Providers - 12 years of age and older Do Not Dilute, Gray Cap
• EUA Fact Sheet for Vaccination Providers - 5 through 11 years of age Dilute Before Use, Orange Cap
For healthcare professionals only